Apoptosis and proliferation factors in renal cance
https://doi.org/10.17650/1726-9776-2008-4-2-16-21
Abstract
The problem of forecasting of a kidney cancer and a choice of a method of adjuvant treatment the advanced forms of this disease remains actual. In the given research the estimation of prognostic importance of apoptotic and proliferative markers in 66 patients with local advanсed and metastatic renal cell carcinoma has been led. Results of the work allow to conclude that the estimation of expression of these markers allows to allocate groups of patients of the high risk requiring careful supervision and treatment.
About the Authors
O. B. Loran
Urology and surgical andrology department of russian medical academy of the post-diploma education
Russian Federation
Russian Federation
G. A. Frank
Moscow research oncology institute named after P.A. Gercen
Russian Federation
Moscow
Russian Federation
Moscow
A. V. Seregin
Urology and surgical andrology department of russian medical academy of the post-diploma education
Russian Federation
Russian Federation
L. E. Zavalishina
Moscow research oncology institute named after P.A. Gercen
Russian Federation
Moscow
Russian Federation
Moscow
U. U. Andreeva
Moscow research oncology institute named after P.A. Gercen
Russian Federation
Moscow
Russian Federation
Moscow
A. A. Seregin
Urology and surgical andrology department of russian medical academy of the post-diploma education
Russian Federation
Russian Federation
N. A. Shustitzkiy
Urology and surgical andrology department of russian medical academy of the post-diploma education
Russian Federation
Russian Federation
References
1. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2004 году. М.; 2005.
2. Mathew A., Devesa S.S., Fraumeni J.F. Jr. et al. Global increases in kidney cancer incidence, 1973–92. Eur J Cancer Prev 2002;11:171–8.
3. Flanigan R.C., Campbell S.C., Clark J.I. et al. Metastatic renal cell carcinoma. Current treatment options. Oncology 2003;4:385–90.
4. Mickisch G.H. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Eur Urol 2003;43:670–9.
5. Linechan S.H., Shipley W.U., Parkinson D.R. Cancer of the kidney and ureter. In: De Vita V.T. Ir., Ed. Cancer: principles and practice of oncology, 4th ed. Philadelphia, J.B. Lippincot; 1993.
6. Гарин А.М., Хлебнов А.В. Справочник практической химиотерапии опухолей. М., Росмэн; 1995.
7. Amato R.J. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177–86.
8. Fossa S., Droz J.P., Pavone-Macaluso M. et al. Vinblastine in Metastatic Renal Cell Carcinoma: EORTC Phase III Trial 30882. Eur J Cancer 1992;28a:878–80.
9. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22:42–60.
10. Pyrhönen S., Salminen E., Ruutu M. et al. Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Carcinoma. J Clin Oncol 1999;17:2859–70.
11. Steiner G., Strander H., Carbin B.E. et al. Recombinante interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomised trial. Acta Oncol 1990;29:155.
12. Papac R.J., Keohane M.F. Hormonal therapy for metastatic renal cell carcinoma combined androgent and prover followed by high dose tamoxifen. Eur J Cancer 1993;29:997–9.
13. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient followup. Radiother Oncol 1999;52:111–21.
14. Huguenin P.U., Kieser S., Glanzmann C. et al. Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points. Int J Rad Oncol Biol Phys 1998;41:401–5.
15. Tretter C.P.G., Ernstoff M.S. Chemotherapy, Hormonal therapy, and Interferons. Genitourinary Oncology, 2nd ed. Edited by N.J. Vogelzang, P.T. Scarding, W.U. Shipley, D.S. Coffey. USA, Lippincott Williams and Wilkins; 1999. p. 248–59.
16. Kim H.L., Seligson D., Liu X. et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;73(5):1496–501.
17. Vasavada S.P., Novick A.C., Williams B.R. P53, Bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51:1057–61.
18. Uzunlar A.K., Sahin H., Yilmaz F. et al. Expression of p53 oncoprotein and Bcl-2 in renal cell carcinoma. Saudi Med J 2005;26:37–41.
19. Cho D.S., Joo H.J., Oh D.K. et al. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 2005;46(1):133–40.
Review
For citations:
Loran O.B., Frank G.A., Seregin A.V., Zavalishina L.E., Andreeva U.U., Seregin A.A., Shustitzkiy N.A. Apoptosis and proliferation factors in renal cance. Cancer Urology. 2008;4(2):16-21. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-2-16-21
Views:
283
Email this article 